Search

everythinglearnresearchcommunity

for

Search:↓

CB-03-01 is a topical anti-androgen with low absorption, offering potential as a side-effect-free alternative to Finasteride/Dutasteride for hair loss. It's in stage 2 clinical trials for acne and showing promise for male pattern baldness.

The conversation discusses the best carrier for RU58841, comparing Ethanol and PEG400. The user seeks advice on which carrier is more effective.

A non-binary transfeminine person experienced significant hair regrowth after starting finasteride, minoxidil, microneedling, and hormone replacement therapy with estradiol. They encourage trans individuals concerned about hair loss to consider estrogen as it has greatly improved their hair condition.

The user is generally happy with their hair transplant results but has concerns about graft density and placement, particularly on the left temple and hairline. They are using finasteride and minoxidil inconsistently, plan to add Priorin, and are considering microneedling and PRP sessions for future care.

Hair loss treatments pyrilutamide and GT20029 discussed. Pyrilutamide approval in 2 years, GT20029 in 5-6+ years.

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.

The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.

A 19-year-old is using oral dutasteride, topical minoxidil, and dermastamping to address hair loss and enhance facial hair growth, experiencing minimal side effects and increased body hair. They report positive results in hairline thickness and temple closure.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

Finasteride may affect male offspring's fertility and hormonal balance, with debates on whether to discontinue use before conception. Some users report no issues, while others highlight the high doses used in rat studies.

Use finasteride or dutasteride with minoxidil for at least a year to improve hair density before considering a hair transplant. A transplant might be needed if medications don't provide sufficient regrowth.

A 21-year-old male is experiencing hair shedding, possibly due to stress from a breakup, and is using minoxidil and drinking green tea to address it. Others suggest stress as a cause and recommend consulting a dermatologist if it persists.

The user is likely at Norwood level 3 with thinning at the crown and temple recession. Treatments like finasteride or minoxidil are suggested to manage hair loss.

A 23-year-old male experienced nipple sensitivity after taking 0.5 mg finasteride for 2.5 months, with blood tests showing increased testosterone and estrogen levels. He stopped finasteride temporarily and seeks advice to prevent gynecomastia.

The conversation discusses starting finasteride 1mg daily for hair loss and mentions a high baseline DHT level. Users comment on the unusually high DHT level and its potential causes.

Hair loss involves more than just DHT, with genetic factors like TRPS affecting hair follicles. Treatments such as Amplifica's AMP-601 and AMP-303 target stem cells for potential hair growth solutions.

A user's experience with the hair loss treatment Pyrilutamide KX-826, which has resulted in some side effects and shedding. The conversation also includes advice for baseline pictures and trying treatments for at least 6 months.

A 23-year-old is experiencing hair loss, primarily at the top middle of the head, and is considering finasteride but is hesitant due to potential side effects. Other users share their positive experiences with finasteride, suggesting it is worth trying, while also discussing the importance of researching and monitoring for any side effects.

The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.

A man with thick, white hair is admired for his genetics, leading to discussions about hair loss and the preference for white hair over balding. Some speculate about the use of treatments like finasteride.

A 24-year-old with a high Norwood scale is seeking advice on hair loss treatments and considering a second hair transplant. They currently use topical finasteride and minoxidil, castor oil, and a derma roller, and are advised to switch to oral dutasteride and minoxidil.

The conversation is about the quality of RU58841 powder from Shaanxi Laon Biotech. The user is inquiring if anyone has experience with this product.

Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.

A 21-year-old experiencing hair loss was prescribed two shampoos and hair vitamins by a dermatologist who suggested seborrheic dermatitis as the cause. However, users in the conversation suggested the hair loss could be male pattern baldness (MPB), recommending monitoring the situation and considering finasteride as a treatment.